Volume 131, Issue 11



March 15, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Atorvastatin is a potential novel therapy for ITP. See the article by Kong et al.

PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke
This plenary paper changes the approach to the study of the role of protease activated receptors in vivo. The investigators describe the generation of 2 mouse lines with distinct point mutations in protease-activated receptor 1 (PAR1) that prevent the cleavage of the receptor by either thrombin or activated protein C.

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
With the emergence of targeted therapies in classical Hodgkin lymphoma, the paradigm of salvage chemotherapy followed by autologous stem cell transplant may have changed. The authors report positive results using brentuximab vedotin plus nivolumab prior to transplant.

The impact of aging on primate hematopoiesis as interrogated by clonal tracking
This work represents a significant advance in the study of aged hematopoiesis. It explores genetic barcoding of hematopoietic stem and progenitor cells, examines the impact of age on hematopoietic reconstitution in primates, and reveals delayed emergence of multilineage clones and skewed hematopoiesis at higher age.

Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients
This article reports that bone marrow endothelial progenitor cells from patients with corticosteroid-resistant immune thrombocytopenia (ITP) are reduced and dysfunctional but can be regenerated with atorvastatin, suggesting a potential novel therapy for ITP.

Splenectomy for immune thrombocytopenia: down but not out
This Perspective discusses the role of splenectomy in ITP. Even in the current era of novel second and third line therapies, splenectomy should stay on the list.


View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.